Antithrombin III Avranches, a New Variant with Defective Serine-Protease Inhibition - Comparison with Antithrombin III Charleville^[*]

Summary

A decreased plasma antithrombin activity in presence or in absence of heparin was discovered in a 47-year-old patient presenting with recurrent venous thromboembolism. The immunoreactive material (AT ΠΙ-IR) was normal. The same biological abnormalities were found in two relatives of the patient, leading to the diagnosis of hereditary qualitative AT III deficiency.

The propositus’ AT III was coeluted with normal AT III from an heparin-sepharose column. An additional step of ion-exchange chromatography on a Mono Q column using a FPLC system (Pharmacia, St-Quentin en Yvelines, France) allowed the purification of a protein which was homogenous in SDS-10% polyacrylamide electrophoresis gel (PAGE). AT III purified from propositus’ plasma, normal plasma and the plasma of the patient known to have an AT III variant with defective protease binding (AT III Charleville) were compared. The specific activities measured as heparin cofactor anti thrombin or factor Xa inhibition in absence of heparin were decreased to half the normal value.

Kinetic studies confirmed a decreased rate of thrombin inhibi-tion for both abnormal AT III preparations. SDS-PAGE experi-ments performed in purified system and immunoblots obtained from plasma showed that the two variants have different behaviour: in the case of AT III Charleville thrombin induced an apparent 5 Δ increase in molecular mass, probably due to a conformational change. AT III Avranches did not form stoechiometric complexes with thrombin, but was unmodified by the protease.

Key words

AT III - Variant - Serine-protease binding site

This work was published in an abstract form in Thrombosis Haemostasis 1987; 58: 38.

• References

• 1 Sorensen PJ, Sas G, Peto I, Blqsko Gy, Kremmer T, Samu A. Distinction of two pathological antithrombin III molecules: antithrombin III “Aalborg” and antithrombin III “Budapest”. Thromb Res 1982; 26: 211-219
• 2 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin “Chicago”: a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-1250
• 3 Jorgensen M, Petersen LC, Thorsen S. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. J Lab Clin Med 1984; 104: 245-256
• 4 Wolf M, Boyer C, Tiipodi A, Meyer D, Larrieu MJ, Mannucci PM. Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III. Blood 1985; 65: 496-500
• 5 Howarth DJ, Samson D, Stirling Y, Seghatchian MJ. Antithrombin III “Northwick Park”: a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity. Thromb Haemostas 1985; 53: 314-319
• 6 Sambrano JE, Jacobson LJ, Reeve EB, Manco-Johnson MJ, Hathaway WM E. Abnormal antithrombin III with defective serine protease binding (antithrombin III “Denver”). J Clin Invest 1986; 77: 887-893
• 7 Aiach M, Nora M, Fiessinger JN, Roncato M, Francois D, Alhenc-Gelas M. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Thromb Res 1985; 39: 559-570
• 8 Aiach M, Francois D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M, Fiessinger JN. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. Br J Haematol 1987; 67: 515-522
• 9 Bjork I, Danielsson A, Fenton JW, Jornvall H. The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett 1981; 126: 257-260
• 10 Stephens AW, Thalley BS, Hirs CH W. Antithrombin-III Denver, a reactive site variant. J Biol Chem 1987; 262: 1044-1048
• 11 Erdjumertt H, Lane DA, Panico M, Di Marzo V, Morris HR. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow J Biol Chem 1988; 263: 5589-5593
• 12 Wolf M, Boyer-Neumann C, Meyer D, Tripodi A, Mannucci PM, Larrieu MJ. Purification and further characterization of antithrombin III Milano: lack or reactivity with thrombin. Thromb Haemostas 1987; 58: 888-892
• 13 Lane DA, Flynn A, Ireland H, Erdjument H, Samson D, Howarth D, Thompson E. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin. Br J Haematol 1987; 65: 451-456